Law360, New York (March 11, 2014, 7:59 PM EDT) -- The Federal Trade Commission said Monday it has the authority to issue reporting requirements that impact just the pharmaceutical industry, and asked a Washington, D.C., federal judge to rule in its favor in a dispute over patent licenses with the Pharmaceutical Research and Manufacturers of America.
The FTC said in a summary judgment motion that the FTC has the authority to require drug makers to report more exclusive patent licenses for antitrust approval under the Hart-Scott-Rodino Act.
“[PhRMA] asserts that Congress intended to prohibit the commission from...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.